Cited 0 times in
Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T01:05:59Z | - |
dc.date.available | 2023-06-02T01:05:59Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194652 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | V.C. Dieras | - |
dc.contributor.googleauthor | M. Martin Jimenez | - |
dc.contributor.googleauthor | C.C.M. O'Sullivan | - |
dc.contributor.googleauthor | J. Sohn | - |
dc.contributor.googleauthor | K. Tryfonidis | - |
dc.contributor.googleauthor | L. Santarpia | - |
dc.contributor.googleauthor | S. Yang | - |
dc.contributor.googleauthor | E.P. Hamilton | - |
dc.identifier.doi | 10.1016/j.annonc.2022.03.226 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0923753422006056 | - |
dc.citation.volume | 33 | - |
dc.citation.number | Supplement 3 | - |
dc.citation.startPage | S222 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Supplement 3) : S222, 2022-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.